Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commentary - EC final report: bark worse than bite?

This article was originally published in Scrip

Executive Summary

On July 8th, 2009, the European Commission reported on its 18-month inquiry into competition in the pharmaceuticals sector. Bill Batchelor of Baker & McKenzie's Brussels antitrust practice describes some of the implications of the much-awaited report.

You may also be interested in...



New EU Strategy Targets Pharma Supply, Affordability & Innovation

A new pharmaceutical strategy is to be published later this year aimed at ensuring the availability and the supply of medicines.

European Court Judgment Changes the Rules for Dominant Companies

Bill Batchelor highlights the far-reaching implications of the AstraZeneca judgment.

AstraZeneca judgement changes the rules for dominant companies

On 1 July 2010 the EU General Court handed down its judgement in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case – barring appeal – is set to cast a long shadow over the activities of patent and regulatory professionals.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel